Specialist Updates 
Oncology

Trastuzumab biosimilar PBS-listed

Among its indications are for patients with HER2-positive advanced adenocarcinoma of the stomach
Clare Pain
0
16 August 2019
Save
Please login to bookmark Close

A biosimilar of trastusumab, Ogivri (Mylan), was listed on the PBS on 1 August.

The biosimilar is available as a 150mg injection and is indicated for HER2-positive early breast cancer in combination with chemotherapy, and possibly also radiotherapy.

Other indications are for locally advanced HER2-positive breast cancer after neoadjuvant chemotherapy and for selected patients with metastatic breast cancer where tumours overexpress HER2.

It is also indicated for certain patients with HER2-positive advanced adenocarcinoma of the stomach or gastro-oesophageal junction.   

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Content that breaches the privacy of other individuals
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .